Drug Profile
Zinpentraxin alfa - Roche
Alternative Names: PRM-151; recombinant human pentraxin-2 - Roche; RG-6354; rhPentraxin-2; rhPTX 2; rhSAP; RO-7490677Latest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Promedior
- Developer Roche
- Class Anti-inflammatories; Antifibrotics; Eye disorder therapies; Glycoproteins; Hepatoprotectants; Recombinant proteins; Urologics
- Mechanism of Action Protein replacements; Transforming growth factor beta1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Myelofibrosis; Scars
- Phase I Crohn's disease
- No development reported Kidney disorders; Lung disorders; Non-alcoholic steatohepatitis
- Discontinued Idiopathic pulmonary fibrosis
Most Recent Events
- 09 Dec 2023 Zinpentraxin alfa is still in phase II trials for Myelofibrosis in Canada, France, Germany, Israel, Italy, Netherlands, the US and UK
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 03 Nov 2023 Roche completes a phase I clinical trials in Crohn's disease (In volunteers) in USA (IV) (ISRCTN12950872)